Skip to main content
. 2020 Mar 13;22(9):1302–1314. doi: 10.1093/neuonc/noaa058

Fig. 1.

Fig. 1

LSD1 immunogenic signature is predictive of survival benefit in pediatric high-grade glioma patients. (A) RNA-Seq pathway analysis performed in LSD1 shRNA transduced LN18 cells. Immune response genes and associated fold changes are shown. (B) RT-qPCR of immune gene signature in LN18 cells with LSD1 shRNA or 1 mM TCP treatment for 24 h analyzed by one-way ANOVA with FDR correction. (C) RT-qPCR of immune gene signature in LN18, DIPG IV, and DIPG VI after 1 mM TCP treatment for 24 h analyzed by one-way ANOVA with FDR correction. (D) Heat map of pHGG patient exome data probed for LSD1 immune gene signature. (E) LSD1 expression of patients expressing high and low levels of gene signature analyzed by unpaired t-test. (F) Survival curves of pHGG patient data subdivided by histone mutation and tumor location and analyzed by log-rank or Wilcoxon tests. *P < 0.05, **P < 0.01, ****P < 0.0001, ns = not significant. At least 3 biological replicates were used for RT-qPCR experiments.